914103-95-0

Basic information

• Product Name: [2-(4-(broMoMethyl)phenyl)ethyl]carbaMic acid tert-butyl ester
• Synonyms: [2-(4-(broMoMethyl)phenyl)ethyl]carbaMic acid tert-butyl ester
• CAS NO: 914103-95-0
• Molecular Formula: C₁₄H₂₀BrNO₂
• Molecular Weight: 314.2181
• Mol File: 914103-95-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [2-(4-(broMoMethyl)phenyl)ethyl]carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(4-(broMoMethyl)phenyl)ethyl]carbaMic acid tert-butyl ester(914103-95-0)
• EPA Substance Registry System: [2-(4-(broMoMethyl)phenyl)ethyl]carbaMic acid tert-butyl ester(914103-95-0)

Safety Data

• Hazardous Substances Data: 914103-95-0(Hazardous Substances Data)

Usage

Description

[2-(4-(bromomethyl)phenyl)ethyl]carbamic acid tert-butyl ester is a chemical compound with a molecular formula C13H18BrNO2. It is the tert-butyl ester of carbamic acid, featuring a benzene ring with a bromomethyl group attached to it. This versatile compound is known for its potential uses in chemical and pharmaceutical research, particularly in the synthesis of new drugs and the development of new materials and biologically active compounds.

Uses

Used in Organic Synthesis:
[2-(4-(bromomethyl)phenyl)ethyl]carbamic acid tert-butyl ester is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, such as nucleophilic substitution and cross-coupling reactions. Its unique structure allows for the creation of a wide range of new compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [2-(4-(bromomethyl)phenyl)ethyl]carbamic acid tert-butyl ester is used as a key intermediate in the synthesis of new drugs. Its chemical properties make it a valuable component in the development of innovative medications, contributing to advancements in healthcare and treatment options.
Used in the Development of New Materials:
[2-(4-(bromomethyl)phenyl)ethyl]carbamic acid tert-butyl ester is also utilized in the development of new materials, thanks to its potential to form various compounds through chemical reactions. This makes it a promising candidate for use in creating novel materials with unique properties for a range of applications.
Used in the Creation of Biologically Active Compounds:
Furthermore, [2-(4-(bromomethyl)phenyl)ethyl]carbamic acid tert-butyl ester is employed in the creation of biologically active compounds, which can have significant implications in the fields of medicine and biology. Its versatility in chemical reactions allows for the synthesis of compounds that can interact with biological systems, potentially leading to new therapies and treatments.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1190890-96-0 (2-(4-tolyl)ethyl)carbamic acid tert-butyl ester 
• 421551-76-0 tert-butyl N-{2-[4-(hydroxymethyl)phenyl]ethyl}carbamate 

Downstream Products

• 914103-94-9 tert-butyl [2-(4-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}phenyl)ethyl]carbamate 
• 914104-01-1 1-[4-(2-aminoethyl)benzyl] piperidin-2-one hydrochloride 
• 914104-03-3 tert-butyl [2-(4-{[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]methyl}phenyl)ethyl]carbamate 
• 914104-05-5 1-[4-(2-aminoethyl)benzyl]-4-ethylpiperazine-2,3-dione hydrochloride 
• 1279558-76-7 [2-(4-(fluoromethyl)phenyl)ethyl]carbamic acid tert-butyl ester 
• 1279558-78-9 2-(4-(fluoromethyl)phenyl)ethylamine 

Relevant articles and documents

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-sytemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

Mechanistic approach of the difference in non-enzymatic hydrolysis rate between the L and D enantiomers of no-carrier added 2-[18F] fluoromethyl-phenylalanine

No-carrier added (n.c.a.) 2-[18F]fluoromethyl-l-phenylalanine was found to be very sensitive to hydrolysis in aqueous solutions. This problem was solved partially by the addition of calcium ions (0.04M), increasing the shelf-life to at least 6h. In this paper the defluorination reaction was studied in detail to elucidate its mechanism. Therefore, L and D enantiomers of 2-[18F]FMP and 4-[18F]FMP were synthesized, as well as 2-[18F]fluoromethyl-phenethylamine and 4-[18F] fluoromethyl-phenethylamine, both decarboxylated 'mimetic' molecules of the amino acid analogues. Radiosynthesis, using a customized Scintomics automatic synthesis hotboxthree module, resulted in a high overall yield and a radiochemical purity of >99%. The defluorination rates of all compounds were studied by HPLC. The L enantiomer of n.c.a 2-[18F]FMP defluorinated seven times faster than the D enantiomer and 2-[18F]fluoromethyl- phenethylamine. Both enantiomers of 4-[18F]FMP and 4-[ 18F]fluoromethyl-phenethylamine were stable. From these data, the reaction mechanism, involving two distinct intramolecular interactions, was derived. First, the interaction between the amine and the benzylic fluorine weakens the carbon-fluorine bond. Secondly, the formation of a second hydrogen bridge between the carboxyl group and one of the benzylic hydrogen atoms renders the fluorine atom even more susceptible to hydrolysis. The latter interaction induces an additional chiral center. The probability of its formation differs considerably between L and D enantiomers of n.c.a. 2-[18F]FMP, which explains the difference in hydrolysis rate. Copyright

THIENOPYRIMIDONE COMPOUND

The present invention relates to a compound represented by the formula: wherein Ar is an optionally substituted ring; A is a spacer having a main chain of 1 to 4 atoms; B is a bond, a C1-10 alkylene group or an oxygen atom; R3 and R5 are each independently a hydrogen atom or a substituent; R4 is an optionally substituted cyclic group or an optionally substituted C1-10 alkyl group; and R1 and R2 are each independently a hydrogen atom or a substituent, or R1 and R2 or R1 and B are bonded to form an optionally substituted nitrogen-containing heterocycle, or R1 and Ar are bonded to form an optionally substituted nitrogen-containing fused heterocycle, or a salt thereof. The thienopyrimidone compound of the present invention has a superior melanin-concentrating hormone receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of obesity and the like.